Literature DB >> 6099974

Plasma renin activity and plasma aldosterone concentrations in untreated Nigerians with essential hypertension.

B Osotimehin, R T Erasmus, A O Iyun, A O Falase, Z Ahmad.   

Abstract

On the basis of existing information we set out to test an hypothesis that 'the blood volume and more specifically total body sodium and sodium disposition in the body play a more important role in blood-pressure regulation and the pathophysiology of hypertension than other regulatory mechanisms in the indigenous African'. To achieve our objective, ninety-eight newly diagnosed unmedicated hypertensives with adequate renal function were admitted to the study. Fifty-one (52%) of the subjects were males while forty-seven (48%) were females. Their ages ranged between 21 and 70 years. All grades of the disease were adequately represented with thirty (31%) being mild, fifty (51%) moderate and eighteen (18.4%) in severe phase of the disease. Blood-pressure measurements and blood samples were obtained in the supine position in all the patients after adequate preparation. Plasma renin activity (PRA) and plasma aldosterone concentrations were measured by specific radioimmunoassays. Contrary to what obtains elsewhere, seventy-six (77%) of our patients were of the low renin status, twelve (12%) of whom had undetectable levels by our assay system. Eighteen (18.4%) had PRA levels in the medium range and five (5.1%) in the high range. In a cohort, forty-two (43%) of our ninety-eight patients, we estimated plasma aldosterone levels. The results obtained showed that the plasma aldosterone concentrations were significantly higher in hypertensives than in our normal controls (P less than 0.01). There was lack of correlation between PRA or plasma aldosterone when compared to mean arterial pressure or serum Na+. These results are discussed in relation to the management of hypertension in our environment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6099974

Source DB:  PubMed          Journal:  Afr J Med Med Sci        ISSN: 0309-3913


  8 in total

1.  Angiotensin converting enzyme inhibition reduces proteinuria in Nigerians with chronic renal disease.

Authors:  A A Ajayi; A T Ajayi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Blood pressure, prevalence of hypertension and hypertension related complications in Nigerian Africans: A review.

Authors:  Okechukwu S Ogah; Ikechi Okpechi; Innocent I Chukwuonye; Joshua O Akinyemi; Basden Jc Onwubere; Ayodele O Falase; Simon Stewart; Karen Sliwa
Journal:  World J Cardiol       Date:  2012-12-26

3.  Enalapril in African patients with congestive cardiac failure.

Authors:  A A Ajayi; M O Balogun; E A Oyewo; G O Ladipo
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

4.  Enalapril and hydrochlorothiazide in hypertensive Africans.

Authors:  A A Ajayi; E A Oyewo; G O Ladipo; A Akinsola
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.

Authors:  A A Ajayi; A O Akintomide
Journal:  J Natl Med Assoc       Date:  1995-07       Impact factor: 1.798

6.  Influence of West African Ethnicity and Gender on Beta-Cell Function and Insulin Sensitivity in Essential Hypertensives Treated with Hydrochlorothiazide and Hydrochlorothiazide-lisinopril Combination.

Authors:  Micheal Olamoyegun; Babatope Kolawole; Adesuyi A L Ajayi
Journal:  J Pharmacol Pharmacother       Date:  2017 Apr-Jun

Review 7.  Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review.

Authors:  A A L Ajayi; O E Ajayi
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2021-10-28

8.  Relationship between Plasma Aldosterone Levels and Left Ventricular Mass in Hypertensive Africans.

Authors:  Adewole Adebiyi; Olubayo Akinosun; Chibuike Nwafor; Ayodele Falase
Journal:  Int J Hypertens       Date:  2013-10-07       Impact factor: 2.420

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.